CD28 and neoplasm: When elongating two second-generation CD28/4-1BB/CD3ζ CARs by a DAP10 domain, Zhao et al. found these receptors to have superior anti-tumor activity against GPC3+ lung cancer, respectively MSLN+ hepatocellular carcinoma and gastric cancer, prolonging the survival of xenograft-bearing mice [194,195].